Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$29.00 – $45.28
59% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $445.48B | $507.79B | $566.78B | $630.60B | $802.75B | $805.16B | $857.54B | $923.40B |
| Cost of revenue | $191.65B | $224.50B | $248.01B | $281.32B | $342.29B | $283.83B | $266.81B | $286.32B |
| Gross profit | $253.84B | $283.29B | $318.77B | $349.27B | $460.46B | $521.32B | $590.74B | $637.07B |
| Gross margin | 57.0% | 55.8% | 56.2% | 55.4% | 57.4% | 64.7% | 68.9% | 69.0% |
| R&D | $40.55B | $48.86B | $53.98B | $61.01B | $75.11B | $78.34B | $99.25B | $90.64B |
| Operating income | $45.04B | $39.90B | $115.09B | $135.83B | $153.56B | $217.03B | $261.16B | $321.78B |
| EBITDA | $78.86B | $90.76B | $155.64B | $192.16B | $222.26B | $262.59B | $342.57B | $355.74B |
| Net income | $35.35B | $47.13B | $104.68B | $139.63B | $169.08B | $158.85B | $239.24B | $230.94B |
| Net margin | 7.9% | 9.3% | 18.5% | 22.1% | 21.1% | 19.7% | 27.9% | 25.0% |
| EPS (diluted) | 189.72 | 253.40 | 562.90 | 750.65 | 834.96 | 859.72 | 1307.00 | 1263.79 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.04T | $1497.53 | $1436.29–$1623.23 | 1 |
| 2027 | $1.11T | $1659.76 | $1591.88–$1799.07 | 1 |
| 2028 | $1.17T | $1795.54 | $1722.11–$1946.24 | 1 |
| 2029 | $1.19T | $1803.25 | $1729.50–$1954.60 | 1 |
Forward consensus · source: Financial Modeling Prep
CHEMICAL WKS RICHTER GED
No one on the platform currently holds RGEDF.
No tracked institution reports a position in RGEDF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-04 | $655.4545 | 2026-06-11 |
| 2025-06-04 | $509.0000 | 2025-06-12 |
| 2024-06-06 | $431.9833 | 2024-06-13 |
No one on the platform has traded RGEDF yet.
| $3.3B |
| — |
| MEPDFMediPal Holdings Corporation | $18.35 | +0.00% | $3.8B | — |
| RHCGFRyman Healthcare Limited | $1.08 | +0.00% | $1.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.0× earnings vs its 0.0× historical median P/E.
Fair value ≈ $33.28 · price $38.65 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.